Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G.

J Clin Oncol. 2019 Jul 24:JCO1901073. doi: 10.1200/JCO.19.01073. [Epub ahead of print]

PMID:
31339826
2.

Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation.

Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Brice P, Morice P, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Gouy S, Chalas C, Egels S, Dhédin N, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N; CAROLéLISA Cooperative Group.

Hum Reprod. 2019 Jun 4;34(6):1083-1094. doi: 10.1093/humrep/dez047.

PMID:
31116405
3.

Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.

Kostopoulou F, Gabillaud C, Chapiro E, Grange B, Tran J, Bouzy S, Degaud M, Ghamlouch H, Le Garff-Tavernier M, Maloum K, Choquet S, Leblond V, Gabarre J, Lavaud A, Morel V, Roos-Weil D, Uzunov M, Guieze R, Bernard OA, Susin SA, Tournilhac O, Nguyen-Khac F; French Innovative Leukemia Organization (FILO) group.

Cancer Med. 2019 Jun;8(6):3131-3141. doi: 10.1002/cam4.2123. Epub 2019 May 7.

4.

Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies.

Poirot C, Fortin A, Dhédin N, Brice P, Socié G, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, Leblanc T, Gabarre J, Delmer A, Badachi Y, Drouineaud V, Chalas C, Egels S, Touraine P, Dommergues M, Lebègue G, Wolf JP, Capron F, Lefebvre G, Boissel N.

Haematologica. 2019 Aug;104(8):e360-e363. doi: 10.3324/haematol.2018.211094. Epub 2019 Feb 14. No abstract available.

5.

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association.

Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

PMID:
30172345
6.

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

Thomas J, Fermé C, Noordijk EM, Morschhauser F, Girinsky T, Gaillard I, Lugtenburg PJ, André M, Lybeert MLM, Stamatoullas A, Beijert M, Hélias P, Eghbali H, Gabarre J, van der Maazen RWM, Jaubert J, Bouabdallah K, Boulat O, Roesink JM, Christian B, Ong F, Bordessoule D, Tertian G, Gonzalez H, Vranovsky A, Quittet P, Tirelli U, de Jong D, Audouin J, Aleman BMP, Henry-Amar M.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1133-1145. doi: 10.1016/j.ijrobp.2017.10.015. Epub 2017 Oct 27.

PMID:
29229324
7.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D; ANRS-CO16 LYMPHOVIR Cohort.

AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.

PMID:
28926410
8.

FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.

Blood. 2017 Sep 14;130(11):1315-1326. doi: 10.1182/blood-2017-02-766691. Epub 2017 Jul 12.

9.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F.

Lancet Haematol. 2017 Jan;4(1):e46-e55. doi: 10.1016/S2352-3026(16)30171-5.

PMID:
28041583
10.

Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, Choquet S, Heudel PE, Leblond V, Gabarre J, Valantin MA, Solas C, Guihot A, Carcelain G, Autran B, Katlama C, Quéro L.

Ann Oncol. 2016 Mar;27(3):397-408. doi: 10.1093/annonc/mdv606. Epub 2015 Dec 17. Review.

PMID:
26681686
11.

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Lazarovici J, Dartigues P, Brice P, Obéric L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, André M, Mounier N, Fermé C.

Haematologica. 2015 Dec;100(12):1579-86. doi: 10.3324/haematol.2015.133025. Epub 2015 Oct 1.

12.

High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.

Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, Gabarre J, Bonnet F, Goujard C, Lambotte O, Boué F, Mounier N, Partisani M, Raffi F, Costello R, Hendel-Chavez H, Algarte-Genin M, Trabelsi S, Marchand L, Raphael M, Taoufik Y, Costagliola D.

Clin Infect Dis. 2015 Nov 1;61(9):1469-75. doi: 10.1093/cid/civ627. Epub 2015 Jul 29.

PMID:
26223997
13.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P; Lymphoma Study Association (LYSA).

Ann Oncol. 2014 Aug;25(8):1622-8. doi: 10.1093/annonc/mdu189. Epub 2014 May 14.

PMID:
24827123
14.

[Radiation therapy of sinonasal natural killer/T-cell lymphoma].

Riet FG, Canova CH, Gabarre J, Ben Hassine S, Kamsu Kom L, Mazeron JJ, Feuvret L.

Cancer Radiother. 2014 Mar;18(2):147-53; quiz 161, 163. doi: 10.1016/j.canrad.2013.11.009. Epub 2014 Jan 22. Review. French.

PMID:
24462054
15.

Recurrent Bordetella holmesii bacteremia and nasal carriage in a patient receiving rituximab.

Nguyen LB, Epelboin L, Gabarre J, Lecso M, Guillot S, Bricaire F, Caumes E, Guiso N.

Emerg Infect Dis. 2013 Oct;19(10):1703-5. doi: 10.3201/eid1910.130345. No abstract available.

16.

Melioidosis and hairy cell leukemia in 2 travelers returning from Thailand.

Rossi B, Epelboin L, Jauréguiberry S, Lecso M, Roos-Weil D, Gabarre J, Grenier PA, Bricaire F, Caumes E.

Emerg Infect Dis. 2013 Mar;19(3):503-5. No abstract available.

17.

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.

Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B.

Eur J Cancer. 2013 Sep;49(13):2869-76. doi: 10.1016/j.ejca.2013.04.029. Epub 2013 May 31.

PMID:
23731832
18.

Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.

Ghesquières H, Stamatoullas A, Casasnovas O, Morschhauser F, Gyan E, Gabarre J, Malphettes M, Clément L, Ferlay C, Brice P.

Leuk Lymphoma. 2013 Nov;54(11):2399-404. doi: 10.3109/10428194.2013.776165. Epub 2013 Mar 13.

PMID:
23410099
19.

Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort study.

Terrier B, Costagliola D, Prevot S, Chavez H, Missy P, Rince P, Costello R, Escaut L, Gabarre J, Joly B, Letranchant L, Le Gouill S, Morineau-Le Houssine P, Simon A, Canioni D, Hermine O, Cacoub P, Taoufik Y, Raphael M, Besson C.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):249-53. doi: 10.1097/QAI.0b013e31828a77f0.

PMID:
23403861
20.

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H.

J Clin Oncol. 2012 Nov 10;30(32):3939-46. doi: 10.1200/JCO.2012.42.2345. Epub 2012 Oct 8.

PMID:
23045585
21.

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte.

Lancet. 2011 Nov 26;378(9806):1858-67. doi: 10.1016/S0140-6736(11)61040-4.

22.

Legionella wadsworthii pneumonia: gram stain usefulness.

Lecsö-Bornet M, Brossier F, Lerat I, Gabarre J, Morelot-Panzini C, Similowski T, Jarlier V.

Med Mal Infect. 2011 Dec;41(12):669-70. doi: 10.1016/j.medmal.2011.09.015. Epub 2011 Oct 28. No abstract available.

PMID:
22036520
23.

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G.

J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11.

PMID:
21747087
24.

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.

Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C.

Haematologica. 2011 Aug;96(8):1136-43. doi: 10.3324/haematol.2010.038109. Epub 2011 May 5.

25.

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G; GELA and GOELAMS.

Haematologica. 2011 Aug;96(8):1128-35. doi: 10.3324/haematol.2010.030320. Epub 2011 Apr 12.

26.

Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant.

Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N; Groupe d'Etude des Lymphomes de l'Adulte.

Leuk Lymphoma. 2011 Jul;52(7):1239-48. doi: 10.3109/10428194.2011.566951. Epub 2011 Apr 4.

PMID:
21463114
27.

Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, van't Veer MB, Noordijk EM, Kluin-Nelemans JC, Lampka E, Thomas J, Lugtenburg PJ, Viterbo L, Carde P, Hagenbeek A, van der Maazen RW, Smit WG, Brice P, van Marwijk Kooy M, Baars JW, Poortmans P, Tirelli U, Leeksma OC, Tomsic R, Feugier P, Salles G, Gabarre J, Kersten MJ, Van Den Neste E, Creemers GJ, Gaillard I, Meijnders P, Tertian G, Reman O, Muller HP, Troncy J, Blanc M, Schroyens W, Voogt PJ, Wijermans P, Rieux C, Fermé C, Henry-Amar M; EORTC-GELA H8 Trial Group.

Lancet Oncol. 2009 Dec;10(12):1160-70. doi: 10.1016/S1470-2045(09)70258-X. Epub 2009 Oct 12.

PMID:
19828373
28.

Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.

Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C.

Ann Oncol. 2009 Dec;20(12):1985-92. doi: 10.1093/annonc/mdp237. Epub 2009 Jun 30.

PMID:
19567453
29.

Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.

Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy.

Blood. 2009 Apr 2;113(14):3307-13. doi: 10.1182/blood-2008-03-148874. Epub 2008 Sep 3.

30.

A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.

Validire P, Fermé C, Brice P, Diviné M, Gabarre J, Bouabdallah K, Fitoussi O, Chaoui D, Pacquement H, Soussain C, Carde P, Salhi R, Zanni M, Decaudin D.

Anticancer Drugs. 2008 Mar;19(3):309-15.

PMID:
18510178
31.

Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.

Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F.

Am J Transplant. 2008 Mar;8(3):707-10. doi: 10.1111/j.1600-6143.2007.02110.x. Epub 2008 Feb 5.

32.

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial.

N Engl J Med. 2007 Nov 8;357(19):1916-27.

33.

Oxidative stress in endometrial hyperplasia.

Gómez-Zubeldia MA, Bazo AP, Gabarre JJ, Nogales AG, Palomino JC.

Menopause. 2008 Mar-Apr;15(2):363-8.

PMID:
17893631
34.
35.

Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.

Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Brière J, Ferme C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte.

J Clin Oncol. 2007 May 1;25(13):1732-40. Epub 2007 Mar 26.

PMID:
17389336
36.

Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.

Vaghefi P, Martin A, Prévot S, Charlotte F, Camilleri-Broët S, Barli E, Davi F, Gabarre J, Raphael M, Poirel HA.

AIDS. 2006 Nov 28;20(18):2285-91.

PMID:
17117014
37.

Pallister-Killian syndrome presenting with a complex congenital heart defect and increased nuchal translucency.

Abad DE, Gabarre JA, Izquierdo AM, López-Sánchez C, García-Martínez V, Izquierdo AG.

J Ultrasound Med. 2006 Nov;25(11):1475-80. No abstract available.

PMID:
17060438
38.

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.

Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D.

J Clin Oncol. 2006 Sep 1;24(25):4123-8. Epub 2006 Aug 8.

PMID:
16896005
39.

AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.

Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C.

Blood. 2006 May 15;107(10):3832-40. Epub 2006 Jan 12.

40.

Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.

Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E.

J Clin Oncol. 2005 Jul 1;23(19):4372-80.

PMID:
15994147
41.

Isolated unilateral pulmonary agenesis: early prenatal diagnosis and long-term follow-up.

Gabarre JA, Galindo Izquierdo A, Rasero Ponferrada M, Orbea Gallardo C, Puente Agueda JM, de la Fuente Pérez P.

J Ultrasound Med. 2005 Jun;24(6):865-8. No abstract available.

PMID:
15914692
42.

Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells.

Boulanger E, Duprez R, Delabesse E, Gabarre J, Macintyre E, Gessain A.

Int J Cancer. 2005 Jul 1;115(4):511-8.

43.

High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.

Gabarre J, Marcelin AG, Azar N, Choquet S, Lévy V, Lévy Y, Tubiana R, Charlotte F, Norol F, Calvez V, Spina M, Vernant JP, Autran B, Leblond V.

Haematologica. 2004 Sep;89(9):1100-8.

44.

The mutator pathway is a feature of immunodeficiency-related lymphomas.

Duval A, Raphael M, Brennetot C, Poirel H, Buhard O, Aubry A, Martin A, Krimi A, Leblond V, Gabarre J, Davi F, Charlotte F, Berger F, Gaidano G, Capello D, Canioni D, Bordessoule D, Feuillard J, Gaulard P, Delfau MH, Ferlicot S, Eclache V, Prevot S, Guettier C, Lefevre PC, Adotti F, Hamelin R.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5002-7. Epub 2004 Mar 26.

45.

[Treatment of malignant non-Hodgkin's lymphoma. Economic impact of rituximab (Mabthera) versus conventional chemotherapy].

Malliti M, Junot H, Fievet MH, Gabarre J, Taright N, Vernant JP, Thuillier A.

Ann Med Interne (Paris). 2003 May;154(3):139-47. French.

PMID:
12910040
46.
47.
48.

Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.

Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E, Mena M, Antinori A, Ammassari A, Talamini R, Vaccher E, di Gennaro G, Tirelli U.

Blood. 2002 Sep 15;100(6):1984-8.

49.

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin F, Hermine O, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte.

J Clin Oncol. 2002 May 15;20(10):2472-9.

50.

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.

Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte.

Hematol J. 2001;2(6):378-84.

PMID:
11920277

Supplemental Content

Loading ...
Support Center